Randomized Trialhigh evidence
Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.
The New England journal of medicine·July 2, 2026·PMID 42384870
Why it mattersThis is the first head-to-head trial of two anti-CD20 therapies in MS, providing direct evidence that rituximab is noninferior to ocrelizumab on MRI outcomes. It supports rituximab as an effective, potentially more accessible option, though the higher infection rate warrants attention.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled